{
    "body": "What is the indication for valbenazine?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25809133", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27819145"
    ], 
    "ideal_answer": [
        "Valbenazine granted breakthrough drug status for treating tardive dyskinesia."
    ], 
    "exact_answer": [
        "Valbenazine granted breakthrough drug status for treating tardive dyskinesia."
    ], 
    "type": "factoid", 
    "id": "58f0b0c070f9fc6f0f000006", 
    "snippets": [
        {
            "offsetInBeginSection": 571, 
            "offsetInEndSection": 747, 
            "text": "VMAT2 inhibitors (e.g. deutetrabenazine and valbenazine) have been studied in the treatment of HD-related chorea, tardive dyskinesia and tics associated with Tourette syndrome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27819145", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": -1, 
            "offsetInEndSection": 76, 
            "text": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25809133", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 810, 
            "offsetInEndSection": 1000, 
            "text": "The FDA lowered approval hurdles for valbenazine due to a successful Phase II trial, which showed a distinctive improvement in tardive dyskinesia symptoms during valbenazine administration. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25809133", 
            "endSection": "abstract"
        }
    ]
}